Key facts
- Altis Biosystems’s last known valuation is $20.0M (Apr 2025).
- It has raised $8.8M across 3 recorded rounds; the latest was Seed Round ($2.1M) in Mar 2025.
- Notable investors include National Institutes of Health, Alexandria Venture Investments, Triangle Tweener Fund, Hatteras Venture Partners, NC Idea — 22 tracked in total.
- Altis Biosystems has filed 4 Form Ds with the SEC since 2020, most recently Apr 2025 ($2.1M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Altis Biosystems
Funding rounds
3 roundsAbout Altis Biosystems
Developer of a stem cell technology designed to recreate the human intestinal epithelium and colonic epithelium for compound screening and microbiome research. The company's technology produces a layer of human or animal intestinal stem and differentiated cells either of the small or large intestines, enabling scientists to develop safe and more effective drugs using normal human intestinal tissue and reducing the need for animal testing.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2015
- Employees
- 27
- Website
- altisbiosystems.com/
- Ownership
- Privately Held (backing)
Altis Biosystems doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Altis Biosystems shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Altis Biosystems in its N-PORT filings yet. We sweep new filings monthly.